MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer
A phase 2 trial of MR-guided adaptive radiotherapy in Rectal cancer, run by Fudan University, now recruiting.
Overview
MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer is a phase 2 interventional study registered as NCT06840665 by Fudan University, with 46 participants planned, started 2024-08-13 and due to reach its primary completion in 2026-08-12. Interventions recorded: PD-1 antibody, Oxaliplatin, Capecitabine. Conditions recorded: Locally Advanced Rectal Cancer.
Linked to the technology MR-guided adaptive radiotherapy because the registry's title names it ("mr guided adaptive radiotherapy") and Rectal cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialOrgan Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy
Shares MR-guided adaptive radiotherapy, Rectal cancer and the tag pipeline.
- TrialA Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
Shares Toripalimab, Oxaliplatin, Capecitabine and the tag pipeline.
- TrialAdaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Shares Rectal cancer, Capecitabine and the tag pipeline.
- TrialPerioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Shares Toripalimab, Oxaliplatin, Capecitabine and the tag pipeline.
- TrialEvaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer
Shares Oxaliplatin, Capecitabine and the tag pipeline.
- TrialA Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
Shares Oxaliplatin, Capecitabine and the tag pipeline.
- TrialA Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Shares Oxaliplatin, Capecitabine and the tag pipeline.
- TrialSOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients
Shares Oxaliplatin, Capecitabine and the tag pipeline.